Zobrazeno 1 - 10
of 40
pro vyhledávání: '"Jean Louis Leclerc"'
Autor:
Marc Estenne, Martine Antoine, Serge Degré, Jean-Luc Vachiery, Georges Niset, Jean Louis Leclerc
Publikováno v:
European Respiratory Journal. 14:1131-1135
The purpose of this study was to investigate the haemodynamic response to dynamic exercise after heart-lung transplantation (HLT). Nine stable HLT recipients (6 males) were studied 12-55 months after transplantation. While sitting on a cycle ergomete
Autor:
Denis Schmartz, Jean-Louis LeClerc, Jean-Marie DeSmet, Chi-Hoang Huynh, Jean Louis Vincent, Anthony P.C. Yim, Song Wan
Publikováno v:
The Journal of Thoracic and Cardiovascular Surgery. 117:1004-1008
Objective: The mechanism involved in the endotoxemia frequently recognized during cardiopulmonary bypass remains unclear. It has also been suggested that endotoxin levels were higher in steroid-pretreated patients undergoing cardiopulmonary bypass. M
Publikováno v:
Chest. 112:676-692
Background Recent study of the inflammatory reactions occurring during and after cardiopulmonary bypass (CPB) has improved our understanding of the involvement of the inflammatory cascade in perioperative injury. However, the exact mechanisms of this
Autor:
Jean Louis Vincent, Jean Louis Leclerc, Jacques Devière, Chi-Hoang Huynh, Luc Barvais, Jean-Marie DeSmet, Denis Schmartz, Song Wan
Publikováno v:
American Heart Journal. 133:335-339
With its antiinflammatory properties, interleukin (IL)-10 may play an important role in limiting complications associated with cardiopulmonary bypass (CPB). We previously demonstrated that pretreatment with steroids can significantly increase IL-10 p
Autor:
Luc Barvais, Jean Louis Leclerc, Song Wan, Jean-Marie DeSmet, M Goldstein, Jean Louis Vincent
Publikováno v:
The Journal of Thoracic and Cardiovascular Surgery. 112(3):806-811
Proinflammatory cytokines, such as tumor necrosis factor–α, interleukin-6, and interleukin-8, and antiinflammatory cytokines, such as interleukin-10, may play an important role in patient responses to cardiopulmonary bypass. We sought to define wh
Autor:
Jean Louis Leclerc, Arnaud Marchant, Haibo Zhang, Michel Goldman, Jean-Marie DeSmet, Martine Antoine, Song Wan, Jean-Luc Vachiery, Jean Louis Vincent
Publikováno v:
The Journal of Thoracic and Cardiovascular Surgery. 111(2):469-477
Cardiac surgery with cardiopulmonary bypass triggers an inflammatory response involving proinflammatory cytokines such as tumor necrosis factor-α, interleukin-6, and interleukin-8. To elucidate the pathophysiology of this cytokine response, we explo
Autor:
Mohammad Shahla, Gaëtan Marecaux, Yves Tabardel, Jean Louis Leclerc, Jean Duchateau, Luc Barvais, Denis Schmartz, Jean Louis Vincent
Publikováno v:
Surgery. 119:76-80
Interleukin (IL)-10 is a potent antiinflammatory cytokine inhibiting the release of tumor necrosis factor--alpha (TNF-alpha) and IL-8 by activated macrophages and polymorphonuclear leukocytes. Cardiopulmonary bypass (CPB) represents a unique situatio
Publikováno v:
The Annals of Thoracic Surgery. 77:312-314
One of the main advantages of an aortic valve homograft in comparison with a mechanical prosthesis is the low incidence of thromboembolism without anticoagulation. Development of an obstructive thrombosis is virtually unknown. We report the case of a
Autor:
Primo G, Jean Louis Leclerc, M Antoine, Alex Lipski, Philippe Lejeune, Christian Melot, Marc Abramowicz, Robert Naeije, J M De Smet
Publikováno v:
American Journal of Respiratory and Critical Care Medicine. 149:881-887
Pulmonary hypertension associated with congestive heart failure carries a risk of right ventricular failure after cardiac transplantation. Few data, however, are available on the hemodynamic behavior of the pulmonary circulation in these patients. We
Autor:
Alain D'Hollander, Jean Louis Leclerc, Luc Barvais, R. J. Kahn, Jean Louis Vincent, Van Nueten L, M Goldstein, Scheijgrond H, De Smet Jm
Publikováno v:
Europe PubMed Central
This prospective, double-blind study used invasive monitoring and echo-Doppler techniques to compare the hemodynamic effects of nebivolol, a new beta 1-selective beta-blocking agent with those of atenolol in patients recovering from coronary artery b